Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Etoposide 28Carboplatin 27atezolizumab 16durvalumab 12Cisplatin 10Topotecan 9Drug Therapy 9PM 01183 8pembrolizumab 5Radiotherapy 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Irinotecan 4Injections 4Immunotherapy 4trilaciclib 3toripalimab 3Temozolomide 3Radiosurgery 3Bevacizumab 3AMG 757 3tislelizumab 2monalizumab 2irinotecan sucrosofate 2enzalutamide 2apatinib 2Platinum 2Nivolumab 2Itraconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Small Cell Lung Carcinoma × MAC-ST-001 × Clear all
NCT06922539 2025-12-15

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

SciTech Development, Inc.

Phase 1 Recruiting
44 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡